[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 34.204.168.209. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Citations 0
This Week in JAMA
July 9, 2008

This Week in JAMA

JAMA. 2008;300(2):141. doi:10.1001/jama.2008.42

Androgen deprivation therapy is often used as an adjunct to surgery or radiation for patients with high-risk prostate cancer. However, some evidence suggests that patients with localized prostate cancer are receiving primary androgen deprivation therapy (PADT) as an alternative to surgery, radiation, or conservative management. In a population-based cohort study of men aged 66 years or older and who did not receive definitive local therapy for clinical stage T1-T2 prostate cancer, Lu-Yao and colleagues assessed the relationship between PADT and conservative management and prostate cancer–specific survival or overall survival. The authors report that PADT was associated with worse 10-year prostate cancer–specific survival and no improvement in overall survival compared with conservative management.

×